Around one in five adults in the UK have metabolic dysfunction-associated steatotic liver disease (MASLD), a condition that often develops silently with no obvious symptoms in its early stages, according to the British Liver Trust. Prevalence has increased 150% since 1990, and one in ten children is now thought to have early signs of the disease, according to major media reports. The disease, formerly known as non-alcoholic fatty liver disease (NAFLD), is a growing public health concern in the UK and globally. Some estimates suggest the figure could be as high as one in three, though this discrepancy affects public perception of risk and resource allocation for screening and remains unresolved. Vanessa Hebditch, director of policy at the British Liver Trust, said in an official statement that the disease often develops silently with no obvious symptoms in its early stages.
MASLD is triggered by metabolic or lifestyle issues, including being overweight, Type 2 diabetes, poor diet, high waist measurement, low physical activity, high cholesterol, and high blood pressure, according to multiple media reports. A related condition, MetALD, combines metabolic issues with alcohol-related liver disease, as reported by several outlets. Nearly one in ten US adults are both obese and drink heavily, increasing the risk of MASLD, Dr Bryant Shuey of the University of Pittsburgh said in a press release. Young to middle-aged adults are most likely to be obese and drink heavily, with around 12% of women aged 26-34 falling into this category, according to major media reports.
Death rates from liver disease in the UK have quadrupled over the past 50 years, according to multiple media reports. Around 90% of liver-related deaths are considered preventable, as reported by several outlets. In the UK, the prevalence rate of MASLD increased by 33% between 1990 and 2023, the biggest rise in western Europe, according to major media reports. Globally, MASLD is projected to affect 1.8 billion people by 2050, a 42% rise from 2023, as reported by major media. These alarming trends underscore the urgent need for public health interventions.
A five to 10% reduction in body weight can dramatically cut liver fat and reverse the disease in some cases, according to multiple media reports. Strength training is one of the most powerful tools against fatty liver, as reported by several outlets. These interventions offer hope for managing and potentially reversing MASLD, though the effectiveness of GLP-1 agonists such as Mounjaro and Wegovy in treating the condition remains an area of active research.
Even one heavy drinking session per month could triple the risk of severe liver damage in people with MASLD, Dr Brian P. Lee, a hepatologist and liver transplant specialist with Keck Medicine, said in a press release. He noted that traditionally, physicians have tended to look at the total amount of alcohol consumed, not how it is consumed, when determining the risk to the liver. He added that the public needs to be much more aware of the danger of occasional heavy drinking and should avoid it even if they drink moderately the rest of the time. With more than half of adults reporting some episodic heavy drinking, this issue is particularly concerning. The specific mechanisms by which binge drinking triples fibrosis risk in MASLD patients are not yet fully understood, and the current rate of undiagnosed MASLD in the general population remains unknown.